Interleukin-12: Biological Properties and Clinical Application

By M. Del Vecchio, E. Bajetta, S. Canova, Michael Lotze, A. Wesa, G. Parmiani, A. Anichini. Clinical Cancer Research, 2007

609 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/3a284f7d24c73fd9a507c8e1bd3a6972d97a855e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. V. Sondak
2. D. Sullivan
3. R. Heller
4. A. Daud
5. A. Riker
6. S. Andrews
7. K. Ugen
8. J. Messina

Citations in the corpus

• Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. (2008, methodology): “No comparable tumor regression was seen in athymic mice after intratumoral plasmid IL-12 electroporation arguing for a role of T-cell immune responses in tumor regression.13 No significant organ, laboratory, or symptomatic toxicity was associated with the electrically mediated delivery of plasmid (p”